Immunotrex Biologics
Immunotrex is a classical R&D based company that develops novel and innovative technologies for the biomedical research sector. Their portfolio includes licensed technologies aimed at enhancing product lines in biomedical fields, with divisions focusing on therapeutics, nanotechnology, cryptography, and renewable energy.
Industries
Nr. of Employees
small (1-50)
Immunotrex Biologics
North Andover, Massachusetts, United States, North America
Products
LPS-neutralizing therapeutic peptides
Engineered peptide candidates designed to bind bacterial LPS and block its interaction with host receptors to mitigate inflammatory and coagulation sequelae.
PEG-based nanoparticle delivery platform
Water-based PEG copolymer nanoparticles (50–80 nm) designed as inert carriers for a variety of molecular cargos and compatible with chemo-enzymatic synthesis workflows.
Hemoglobin-encapsulating synthetic blood platform
PEG-based nanoparticle formulations intended to encapsulate human hemoglobin for development of synthetic red blood cells and plasma substitutes with design goals for extended circulation.
Solid-phase photobiological hydrogen production technology
A solid-phase photobiological process designed to increase hydrogen and biofuel component yields relative to conventional photobiological methods (solid-phase high-yield approach).
RNAi therapeutic delivery platform for oncology
A delivery approach employing capsid and targeting arm components to deliver hairpin RNAi oligomers intended to inhibit growth of cancer cells via RNA interference.
LPS-neutralizing therapeutic peptides
Engineered peptide candidates designed to bind bacterial LPS and block its interaction with host receptors to mitigate inflammatory and coagulation sequelae.
PEG-based nanoparticle delivery platform
Water-based PEG copolymer nanoparticles (50–80 nm) designed as inert carriers for a variety of molecular cargos and compatible with chemo-enzymatic synthesis workflows.
Hemoglobin-encapsulating synthetic blood platform
PEG-based nanoparticle formulations intended to encapsulate human hemoglobin for development of synthetic red blood cells and plasma substitutes with design goals for extended circulation.
Solid-phase photobiological hydrogen production technology
A solid-phase photobiological process designed to increase hydrogen and biofuel component yields relative to conventional photobiological methods (solid-phase high-yield approach).
RNAi therapeutic delivery platform for oncology
A delivery approach employing capsid and targeting arm components to deliver hairpin RNAi oligomers intended to inhibit growth of cancer cells via RNA interference.
Services
Technology licensing and collaboration
Licensing of R&D-developed technologies and collaboration with academic and industry partners for further development and commercialization.
Cryptography development for biomedical data security
Development and application of elliptic-curve cryptographic methods for secure data exchange and authentication in biomedical contexts.
Technology licensing and collaboration
Licensing of R&D-developed technologies and collaboration with academic and industry partners for further development and commercialization.
Cryptography development for biomedical data security
Development and application of elliptic-curve cryptographic methods for secure data exchange and authentication in biomedical contexts.
Expertise Areas
- Nanoparticle-based drug delivery
- Peptide therapeutics for endotoxin/anti-sepsis applications
- RNA interference (RNAi) delivery for oncology
- Synthetic red blood cell and plasma substitute development
Key Technologies
- RNA interference (RNAi)
- PEG-based nanoparticles
- Phage/viral-derived delivery vectors
- Therapeutic peptide design